As a mage, I just want to pursue the truth

Chapter 63 The Eve of Listing
Rice's new machines over the years are always the hottest when they first come out, but the stock is insufficient and needs to be rushed.

This is also the hunger marketing that rice has always been criticized, playing monkeys.

When the production capacity of the new rice machine comes up, it will not be as good as the new machine in stock from friends, so it can only be sold at a reduced price.

The price reduction made the rice fans who bought the new machine feel that they were losing money. I bought it half a month earlier and lost [-], and a month later I lost [-].

Might as well be sure next time.

Compared with the new Mimi machine before, this time the Mi mix 4 is more popular and it is more difficult to grab the goods. The goods are released at [-]:[-] in the morning and they are gone within five seconds.

Lei Jun's daily microblog is:

"Boss Lei's new plane is on the way!"

"Can the output go up?"

"Can you stop playing monkeys this time? I really want to buy Mi 6 nails this time."

"Mr. Lei, why don't we go to the factory to screw the screws ourselves?"

"It's not shameful to screw the screws in person, but it's shameful to play tricks on fans every day."

The performance of Mi mix4, the first brain-computer connected mobile phone, exceeded expectations, which made the listing of Kechuang Biotech on the Science and Technology Innovation Board even more expected by shareholders.

Kechuang Bio's quarterly report in the first quarter maintained a high growth rate, and its total operating income in a single quarter exceeded 2020 billion yuan for the whole of 22.71. The main source of income is the production and sales of endorphins and patent licensing.

The non-net profit deducted in the first quarter was as high as 10.745 billion, and the net profit rate was 47.3%, close to 50.00%.

This is due to the fact that the profits from brain-computer connection patent authorization have not yet been released.

At this time, Kechuang Biology has completed the inquiry and rectification stage of Shenhai Stock Exchange, and has entered the issuance registration process with the China Securities Regulatory Commission.

In this step, the China Securities Regulatory Commission needs to make a decision on whether to agree or not to the registration application of Kechuangbiology within 20 working days.

With Kechuang Bio's own qualifications and profitability, the China Securities Regulatory Commission has no reason to reject it, especially since it is a high-tech enterprise that is completely local to China.

Huaguo people have an absolute controlling stake in it, and their nationality has not been changed for tax avoidance even on the eve of the listing.

The outside world agrees that the Huaguo Securities Regulatory Commission will pass the listing approval of Kechuang Bio as soon as possible.

On forums such as Dongfang Fortune's Stock Bar, Flush Stock Bar, and Xueqiu, discussions on science and technology creation are extremely hot.

"The valuation of 4072.93 billion RMB is not high at all. Kechuang Bio's profit in the first quarter was 10.745 billion RMB. If the value of endorphins is counted alone, this valuation must be high.

But everyone should take into account that Kechuangbio is the only player in the field of brain-computer connection. At present, there is no brain-computer connection company in China that can see the taillights of Kechuangbio.

Kechuang Bio has signed patent licensing contracts with first-line domestic and foreign mobile phone brands such as Rice, OV, Huawei, Samsung, and Apple this year. The patent licensing here is calculated according to the number of brain-computer connections to mobile phones.

根据IDC发布的2020年上半年华国手机高端市场容量在2350万台，我算全年是4700万台，预计2021年高端市场跟2020年保持不变，那么也时4700万台。

Among them, the proportion of brain-computer connection to mobile phones should be 30.00% based on the lower limit. Here is 1410 million units, and the patent authorization fee for a single brain-computer connection to mobile phones is 200 yuan.

I am counting on the lower limit of the brain-computer connection patent technology authorization alone, and the annual profit contributed by this part in 2021 will also be 28.2 billion yuan.

And the proportion of brain-computer connection to mobile phones is 30.00% is the worst case, considering the factor that the production capacity cannot be increased.

More importantly, the profit of brain-computer connection is basically net profit. Kechuang Biotech adopts the same strategy as Qualcomm in the field of brain-computer connection. I only do technology licensing and technology research and development.

It is estimated that Kechuang Bio's annual profit in 2021 will be at least 70 billion yuan.

A company holds the patents of endorphin and brain-computer connection, and these two subdivisions of science and technology have formed an absolute field.

Is the valuation of 4072.93 billion really expensive?
In my opinion, Kechuang Bio’s listing at this valuation is giving money to everyone.You have not seen that a large number of companies on the Science and Technology Innovation Board are still in a state of loss, and a large number of biomedical companies on the ChiNext Board and the Main Board enjoy a price-earnings ratio of more than 100.

Kechuang Bio's price-earnings ratio is less than [-], and it is a high-growth technology company.

This valuation is really not high at all.

From the perspective of future profit forecasts, with the release of brain-computer connection chip production capacity, Kechuangbio's profits from brain-computer connection patents can still maintain a high growth trend.

The second-phase production base of endorphin has also started construction, and this part of the profits will be gradually released in the future.

Endorphins not only have an analgesic effect, but also have a very important effect on reducing drug and even dupin addiction.

It has substitutes for pain relief, but no substitute for reducing drug addiction.It can be said that endorphin is to Kechuang Biotech as growth hormone is to Changchun Hi-tech, and Pien Tze Huang is to Pien Tze Huang.

However, Kechuangbio does not walk on one leg like those two companies, it also has a brain-computer connection.

The current brain-computer connection is only a superficial application in this field. In the future, the development of brain-computer connection patents in English, Arabic and other languages ​​will be the first to maintain high profit growth for many years.

The second is the application of brain-computer connection in other fields. I don't understand the technical things, but judging from the rapid development of scientifically innovative creatures, I believe that future scientifically innovative creatures are more worth looking forward to.

The only thing that makes me unsatisfied is the listed stock price of Kechuang Bio, with a total share capital of 4 million shares and an issue price of 1018.23 yuan.

This price is only the listing price. When it is officially listed, it will definitely be hyped up instantly. The price per lot is too high, which is not conducive to retail investors.

Personally, I feel that Kechuang Biotech will become exclusive to institutions just like Moutai after it goes public.

The price of retail investors buying and selling a lot is more than 20, and it may be more than [-] in the future. This price is difficult to withstand fluctuations.

But no matter what the listing price of Kechuangbio is, I will buy it and keep it, and grow together with the great company! "

In places like stock bars, old stockholders usually have a calculator in their hands that they can press quickly, and the company's profits and future profits are not far behind.

But most of those who can hang around in A shares for many years without losing money have some unique skills.

"I have always agreed with a saying that Sci-Tech Biotech is to the Science and Technology Innovation Board just like the Ningde era is to the ChiNext.

Since its establishment, the Science and Technology Innovation Board has not had a leader like the main board and the Science and Technology Innovation Board. When Kechuang Biotech completed the B round of investment, I realized from the news that Kechuang Biotech is the leader of the Science and Technology Innovation Board. .

How can the giant dragon of the Science and Technology Innovation Board fly without the leader?
Huaguo has been advocating independent innovation and technological power over the years. In my opinion, Kechuangbio perfectly interprets these eight words. "

(End of this chapter)